Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Zotefoams (ZTF) by Hot Stock Rockets in ShareProphets
- Neutral Ceres Power Holdings (CWR) by Goldman Sachs
- Sell Bunzl (BNZL) by Goldman Sachs
- Buy Anglo American (AAL) by Stephen Wright in The Motley Fool
- Hold AstraZeneca (AZN) by Ben McPoland in The Motley Fool
- Hold BAE Systems (BA.) by Ben McPoland in The Motley Fool
- Buy Land Securities Group (LAND) by Robert Stephens (Telegraph) in The Telegraph - Questor
- Buy Greggs (GRG) by Ben McPoland in The Motley Fool
- Sell Inspired (INSE) by Steve Moore in ShareProphets
- Neutral Schroders (SDR) by JP Morgan
- Sell Jaywing (JWNG) by Steve Moore in ShareProphets
- Sell Jubilee Metals Group (JLP) by Tom Winnifrith in ShareProphets
- Sell Jubilee Metals Group (JLP) by Steve Moore in ShareProphets
- Avoid Shearwater Group (SWG) by Steve Moore in ShareProphets
- Sell Tribe Technology (TRYB) by Steve Moore in ShareProphets
- Outperform Hollywood Bowl Group (BOWL) by RBC Capital
- Buy JD Sports Fashion (JD.) by Harvey Jones in The Motley Fool
- Hold Legal & General Group (LGEN) by Harvey Jones in The Motley Fool
- Sell Gelion (GELN) by Steve Moore in ShareProphets
- Buy GSK (GSK) by Harvey Jones in The Motley Fool
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 59 open tips for Shield Therapeutics (STX)
| Latest Bid : 2.70p | Latest Ask : 2.80p |
| High Today : 2.80p | Low Today : 2.70p |
| This Years High : 7.65p | This Years Low : 1.23p |
| Volume : 1,589,621 | MKT Cap : £21.9M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 3.45% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -64.71% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -61.97% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 65.00% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 80.49% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 2.70p | Latest Ask : 2.80p |
| High Today : 2.80p | Low Today : 2.70p |
| This Years High : 7.65p | This Years Low : 1.23p |
| Volume : 1,589,621 | MKT Cap : £21.9M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 3.45% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -64.71% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -61.97% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 65.00% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 80.49% |